This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Global Survey Reveals People Want More Investment And Faster Access To New Cancer Treatments

INDIANAPOLIS, Jan. 28, 2013 /PRNewswire/ -- PACE ( Patient Access to Cancer care Excellence), a Lilly Oncology initiative, announces the following webcast:             

What:        PACE Cancer Perception Index webcastWhen:       Wednesday, January 30, 2013, from 11:00 a.m. to 12:00 p.m. ESTWhere:      http://www.videonewswire.com/event.asp?id=91886 How:         Live over the Internet; simply register via the address above 

  • The public's cancer IQ is rising, but myths persist. They recognize cancer progress, but want faster results. They have a high interest in clinical trial participation and sharing results. Still, tough questions and concerns remain, such as how much money should be spent on cancer treatment for an extra year of life and who should pay for it.
  • This survey of 4,341 individuals in the United States, France, Germany, Italy, Japan and the United Kingdom was commissioned by Lilly Oncology and conducted by GfK, one of the world's leading research companies.
  • PACE, a Lilly Oncology initiative, is an emerging global network of collaborations between industry and other sectors intended to improve public policies that determine the accessibility, speed and value of progress against cancer. 

 

 

SOURCE Lilly Oncology

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs